In this work we aim to test the potential use of the MMP‐2/‐9 activatable CPPs for antitumor therapy upon systemic administration of the nanoparticles consisting of CPPs and plasmid DNA (pDNA) that expresses short hairpin RNA against VEGF (shVEGF) to tumor‐bearing mice. This evidence concerns the gene VEGFA and neoplasm.